There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...

Arvinas, Inc. (ARVN) has been beaten down lately with too much selling pressure. While the stock has lost 54.9% over the past ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients lived without the disease worsening, but failed to achieve statistically ...

Trial results show vepdegestrant, a protein-degrading drug Arvinas is developing with Pfizer, improved on fulvestrant in a ...

Vepdegestrant did not improve progression-free survival broadly but saw improvements in one specific patient cohort. Arvinas’ ...

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

Arvinas’ cash burn and lack of pipeline candidates hurt its outlook. See why ARVN stock is a sell, despite a healthy cash ...

Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a report issued on Tuesday, March 18th. Cantor Fitzgerald analyst L. Watsek now forecasts that the ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...